1. Home
  2. INCY vs HLI Comparison

INCY vs HLI Comparison

Compare INCY & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INCY
  • HLI
  • Stock Information
  • Founded
  • INCY 1991
  • HLI 1972
  • Country
  • INCY United States
  • HLI United States
  • Employees
  • INCY N/A
  • HLI N/A
  • Industry
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • HLI Investment Managers
  • Sector
  • INCY Health Care
  • HLI Finance
  • Exchange
  • INCY Nasdaq
  • HLI Nasdaq
  • Market Cap
  • INCY 17.0B
  • HLI 14.4B
  • IPO Year
  • INCY 1993
  • HLI 2015
  • Fundamental
  • Price
  • INCY $104.52
  • HLI $173.72
  • Analyst Decision
  • INCY Buy
  • HLI Hold
  • Analyst Count
  • INCY 19
  • HLI 9
  • Target Price
  • INCY $89.19
  • HLI $205.38
  • AVG Volume (30 Days)
  • INCY 2.8M
  • HLI 553.2K
  • Earning Date
  • INCY 10-28-2025
  • HLI 10-30-2025
  • Dividend Yield
  • INCY N/A
  • HLI 1.38%
  • EPS Growth
  • INCY 3878.02
  • HLI 26.59
  • EPS
  • INCY 5.90
  • HLI 6.19
  • Revenue
  • INCY $4,813,105,000.00
  • HLI $2,565,361,000.00
  • Revenue This Year
  • INCY $19.33
  • HLI $14.85
  • Revenue Next Year
  • INCY $10.47
  • HLI $13.67
  • P/E Ratio
  • INCY $17.60
  • HLI $28.09
  • Revenue Growth
  • INCY 18.09
  • HLI 21.00
  • 52 Week Low
  • INCY $53.56
  • HLI $137.99
  • 52 Week High
  • INCY $109.28
  • HLI $211.78
  • Technical
  • Relative Strength Index (RSI)
  • INCY 68.82
  • HLI 30.03
  • Support Level
  • INCY $103.77
  • HLI $180.17
  • Resistance Level
  • INCY $109.28
  • HLI $180.98
  • Average True Range (ATR)
  • INCY 3.82
  • HLI 5.70
  • MACD
  • INCY -0.06
  • HLI -0.80
  • Stochastic Oscillator
  • INCY 75.05
  • HLI 4.94

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About HLI Houlihan Lokey Inc.

Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.

Share on Social Networks: